Li Auto estimates $14.7b net proceeds in global offering

The bulk of the proceeds will be used to fund R&D initiatives.

New energy passenger vehicles automaker, Li Auto, estimated it will generate some $14.7b in net proceeds from its global offering.

The company, based in China, will be setting its offer prices at not more than $150 per offer share.

Of the 100 million shares, 10 million will be for Hong Kong Public Offering, whilst the remaining 90 million will be for the international offering.

Some 45% of the net proceeds, or approximately $6.6b, will be earmarked for research and development in the next 12 to 36 months.

Around $2.9b of this will fund research and development (R&D) of high-power charging battery-electric vehicles technologies, platforms, and future models; $2.2b for intelligent vehicle and autonomous driving technologies.

In addition, some $1.5b will fund R&D extended-range electric passenger vehicles models in the next 12 to 30 months.

Another 45% will fund infrastructure expansion and marketing and promotion; whilst the remaining 10%, or approximately, $1.5b, will be used as working capital and other general corporate purposes to support our business operation and growth in the next 12 months.

Follow the link for more news on

Join Hong Kong Business community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Exclusives

Hong Kong Residency rule could boost office sector
The ultra-rich are also expected to set up family offices in the city.
Allegrow Biotech engineers technology to activate immune cells
The startup’s invention can be used to treat and potentially cure diseases like cancer.
Healthcare
Renminbi rise to fuel Bank of China HK’s growth
The lender expects the currency to be used more often in cross-border deals.
Retail Banking